Use the journals feature with a free QxMD account.

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Get Started

Journals Biotechnology Healthcare

Biotechnology Healthcare

Follow Journal ＋

#21

JOURNAL ARTICLE

Biologics clinical trials, research, and FDA actions.

Michael D Dalzell

No abstract text is available yet for this article.

23091426

2012: Biotechnology Healthcare

#22

JOURNAL ARTICLE

Innovation flourishes at a time of benefit coverage uncertainty.

F Randy Vogenberg

No abstract text is available yet for this article.

23091425

2012: Biotechnology Healthcare

#23

JOURNAL ARTICLE

Seeing daylight.

Katherine T Adams

No abstract text is available yet for this article.

23091424

2012: Biotechnology Healthcare

#24

JOURNAL ARTICLE

Demand for specialty drugs increasing.

Katherine T Adams

No abstract text is available yet for this article.

22876214

2012: Biotechnology Healthcare

#25

JOURNAL ARTICLE

Vanderbilt pioneers bedside genetics.

Bob Carlson

No abstract text is available yet for this article.

22876213

2012: Biotechnology Healthcare

#26

JOURNAL ARTICLE

FDA Readies New Guidance and User Fee Program for Biosimilars: Drug interchangeability and user fees are contentious issues the FDA must resolve. Is the FDA up to the task?

Stephen Barlas

No abstract text is available yet for this article.

22876212

2012: Biotechnology Healthcare

#27

JOURNAL ARTICLE

Medical Process Patents Declared Invalid: The Prometheus case restricts patent protection and the growth of personalized medicine.

Joanna T Brougher

No abstract text is available yet for this article.

22876211

2012: Biotechnology Healthcare

#28

JOURNAL ARTICLE

Next Generation Sequencing: The Next Iteration of Personalized Medicine: Next generation sequencing, along with expanding databases like The Cancer Genome Atlas, has the potential to aid rational drug discovery and streamline clinical trials.

Bob Carlson

No abstract text is available yet for this article.

22876210

2012: Biotechnology Healthcare

#29

JOURNAL ARTICLE

New care delivery models: where do biologics fit?

Steven R Peskin

No abstract text is available yet for this article.

22876209

2012: Biotechnology Healthcare

#30

JOURNAL ARTICLE

Biologics and the Principles of Health Insurance: What is the purpose of health insurance? This review of basic insurance concepts provides a context for discussions about coverage of biologics.

(no author information available yet)

No abstract text is available yet for this article.

22876208

2012: Biotechnology Healthcare

#31

JOURNAL ARTICLE

Part 1: Distribution models for biologics and other specialty pharmaceutical products: In this first of a two-part series, we examine the distribution landscape for specialty pharmaceuticals. A manufacturer's strategy for the flow of product to patient has important implications for payers and for the success of a new biologic therapy.

Jack McCain

No abstract text is available yet for this article.

22876207

2012: Biotechnology Healthcare

#32

JOURNAL ARTICLE

The accelerated approval debate: faster FDA drug approvals may mean less efficacy data.

John Carroll

No abstract text is available yet for this article.

22876206

2012: Biotechnology Healthcare

#33

JOURNAL ARTICLE

Biologics clinical trials, research, and FDA actions.

Michael D Dalzell

No abstract text is available yet for this article.

22876205

2012: Biotechnology Healthcare

#34

JOURNAL ARTICLE

Healthcare renewal.

Katherine T Adams

No abstract text is available yet for this article.

22876204

2012: Biotechnology Healthcare

#35

JOURNAL ARTICLE

Oncology costs must be reined in, say payers.

Katherine T Adams

No abstract text is available yet for this article.

22606081

2012: Biotechnology Healthcare

#36

JOURNAL ARTICLE

Biotechnology Healthcare's 2011 Editorial Index.

(no author information available yet)

No abstract text is available yet for this article.

22606080

2012: Biotechnology Healthcare

#37

JOURNAL ARTICLE

Saving dollars, preventing disappointment.

Bob Carlson

No abstract text is available yet for this article.

22606079

2012: Biotechnology Healthcare

#38

JOURNAL ARTICLE

Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety.

Erwin A Blackstone, Joseph P Fuhr

Biosimilars are here, but there's no clear pathway yet for their approval. Difficult realities about their effect on drug prices, innovation, and competition need to be faced.

22606078

2012: Biotechnology Healthcare

#39

JOURNAL ARTICLE

In Search of the Perfect Business Model: As personalized medicine moves into the mainstream, makers of diagnostics must face a new economic reality. How to develop a value proposition in a healthcare market that is becoming increasingly elastic?

Bob Carlson

As personalized medicine edges toward the mainstream, economic realities threaten its existence. But without companion diagnostics, "getting the right drug to the right person" could wind up being just a slogan. What's the right business model?

22606077

2012: Biotechnology Healthcare

#40

JOURNAL ARTICLE

A conversation with cheryl larson: vice president, midwest business group on health.

Michael D Dalzell

By 2017, 40 percent of medical spend will be on biologics. It's time for employers to learn how to manage these drugs.

22606076

2012: Biotechnology Healthcare